View Clinical Trial (Medical Research Study)

A Phase II Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas - NCT00880581-94305(Clinical Trial 284024)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Stanford
State:  
CA
Zip Code: 94305
Conditions: Lymphoma, Non-Hodgkin - Lymphoma - Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell - Lymphomas: Non-Hodgkin
Purpose: To assess the feasibility of using intra-tumoral PF-3512676 in combination with local radiation as a therapy for lowgrade b-cell lymphoma.
Study summary:
Criteria: Inclusion Criteria:1. Biopsy confirmed low-grade B-cell lymphoma, specifically, follicular grade 1 or 2, marginal zone or small lymphocytic lymphoma, of any initial stage. Patients may be either treatment-naïve or relapsed from or refractory to prior therapy. Fifteen treatment-naïve and 15 relapsed/refractory patients will be enrolled. 2. Patients must have at least one site of disease that is accessible for intratumoral injection of PF-3512676 percutaneously 3. Tumor specimens must be available for immunological studies either from a previous biopsy or a new biopsy obtained before the initiation of the study. 4. Patients must have measurable disease other than the injection site or biopsy site. 5. ECOG Performance Status of 1 or better (corresponds to Karnofsky Performance Status (KPS) of >= 70) 6. Patients must be 18 years of age or older. 7. Adequate bone marrow function: WBC >= 2,000/uL; platelet count >= 75,000/mm3; ANC>= 1000. 8. Adequate renal function: serum creatinine <= 2.0mg/dL. 9. Adequate hepatic function: bilirubin <=1.5 mg/dL; SGOT/SGPT < 3 x upper limit of normal 10.Required wash out periods for prior therapy: 1. Topical therapy: 2 weeks 2. Chemotherapy: 4 weeks 3. Radiotherapy: 4 weeks 4. Other investigational therapy: 4 weeks 5. Rituximab: 12 weeks 11.Patients of reproductive potential and their partners must agree to use an effective (>90% reliability) form of contraception during the study and for 4 weeks following the last study drug administration. 12.Women of reproductive potential must have negative urine pregnancy test. 13.Life expectancy greater than 4 months. 14.Able to comply with the treatment schedule. 15.Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:A patient may not be enrolled in the trial if any of the following criteria are met: 1. Pre-existing autoimmune or antibody mediated disease including: systemic lupus, erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia, but excluding controlled thyroid disease, or the presence of autoantibodies without clinical autoimmune disease. 2. Known history of human immunodeficiency virus (HIV). 3. Patients with active infection or with a fever >38.50 C within three days prior to the first scheduled treatment. 4. CNS metastases 5. Prior malignancy (active within 5 years of screening) except basal cell or completely excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell carcinoma of the cervix. 6. History of allergic reactions attributed to compounds of similar composition to PF-3512676 7. Current anticoagulant therapy (ASA <= 325 mg per day allowed). 8. Significant cardiovascular disease (i.e. NYHA class 3 congestive heart failure; myocardial infarction with the past 6 months; unstable angina; coronary angioplasty with the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias). 9. Pregnant or lactating. 10. Any other medical history, including laboratory results, deemed by the investigator to be likely to interfere with their participation in the study, or to interfere with the interpretation of the results. The principal investigator may grant a protocol exemption in cases where a patient would be ineligible based on one or more exclusion criteria but would be a good candidate for the study. In this case, a note to file must be generated to explain the inclusion of the patient.
Study is available at: Stanford University School of Medicine
Stanford, CA 94305
United States

Primary Contact:
Emily Troutner
Email: troutner@stanford.edu
Phone: 650-725-4968

Secondary Contact:
Emily Troutner
Email: troutner@stanford.edu
Phone: (650) 725-4968
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.